Browsing by Author "Zhu, Xiangzhu"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Associations of circulating saturated long-chain fatty acids with risk of mild cognitive impairment and Alzheimer’s disease in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort
    (Elsevier, 2023) Fan, Lei; Borenstein, Amy R.; Wang, Sophia; Nho, Kwangsik; Zhu, Xiangzhu; Wen, Wanqing; Huang, Xiang; Mortimer, James A.; Shrubsole, Martha J.; Dai, Qi; Alzheimer’s Disease Neuroimaging Initiative; Radiology and Imaging Sciences, School of Medicine
    Background: No study has examined the associations between peripheral saturated long-chain fatty acids (LCFAs) and conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD). This study aimed to examine whether circulating saturated LCFAs are associated with both risks of incident MCI from cognitively normal (CN) participants and incident AD progressed from MCI in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Methods: We conducted analysis of data from older adults aged 55-90 years who were recruited at 63 sites across the USA and Canada. We examined associations between circulating saturated LCFAs (i.e., C14:0, C16:0, C18:0, C20:0) and risk for incident MCI in CN participants, and incident AD progressed from MCI. Findings: 829 participants who were enrolled in ADNI-1 had data on plasma saturated LCFAs, of which 618 AD-free participants were included in our analysis (226 with normal cognition and 392 with MCI; 60.2% were men). Cox proportional-hazards models were used to account for time-to-event/censor with a 48-month follow-up period for the primary analysis. Other than C20:0, saturated LCFAs were associated with an increased risk for AD among participants with MCI at baseline (Hazard ratios (HRs) = 1.3 to 2.2, P = 0.0005 to 0.003 in fully-adjusted models). No association of C20:0 with risk of AD among participants with MCI was observed. No associations were observed between saturated LCFAs and risk for MCI among participants with normal cognition. Interpretation: Saturated LCFAs are associated with increased risk of progressing from MCI to AD. This finding holds the potential to facilitate precision prevention of AD among patients with MCI.
  • Thumbnail Image
    Item
    Author Correction: Magnesium intake and mortality due to liver diseases: Results from the Third National Health and Nutrition Examination Survey Cohort
    (Springer Nature, 2019-05-01) Wu, Lijun; Zhu, Xiangzhu; Fan, Lei; Kabagambe, Edmond K.; Song, Yiqing; Tao, Menghua; Zhong, Xiaosong; Hou, Lifang; Shrubsole, Martha J.; Liu, Jie; Dai, Qi; Epidemiology, School of Public Health
    A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
  • Thumbnail Image
    Item
    Intakes of magnesium, calcium and risk of fatty liver disease and prediabetes
    (Cambridge, 2018-08) Li, Wenshuai; Zhu, Xiangzhu; Song, Yiqing; Fan, Lei; Wu, Lijun; Kabagambe, Edmond; Hou, Lifang; Shrubsole, Martha; Liu, Jie; Dai, Qi; Epidemiology, School of Public Health
    Objective Obesity and insulin resistance play important roles in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Mg intake is linked to a reduced risk of metabolic syndrome and insulin resistance; people with NAFLD or alcoholic liver disease are at high risk of Mg deficiency. The present study aimed to investigate whether Mg and Ca intakes were associated with risk of fatty liver disease and prediabetes by alcohol drinking status. Design We analysed the association between Ca or Mg intake and fatty liver disease, prediabetes or both prediabetes and fatty liver disease in cross-sectional analyses. Setting Third National Health and Nutrition Examination Survey (NHANES III) follow-up cohort of US adults. Subjects Nationally representative sample of US adults in NHANES (n 13 489). Results After adjusting for potential confounders, Mg intake was associated with approximately 30 % reduced odds of fatty liver disease and prediabetes, comparing the highest intake quartile v. the lowest. Mg intake may only be related to reduced odds of fatty liver disease and prediabetes in those whose Ca intake is less than 1200 mg/d. Mg intake may also only be associated with reduced odds of fatty liver disease among alcohol drinkers. Conclusions The study suggests that high intake of Mg may be associated with reduced risks of fatty liver disease and prediabetes. Further large studies, particularly prospective cohort studies, are warranted to confirm the findings.
  • Thumbnail Image
    Item
    Magnesium intake and mortality due to liver diseases: Results from the Third National Health and Nutrition Examination Survey Cohort
    (Nature Publishing group, 2017-12-20) Wu, Lijun; Zhu, Xiangzhu; Fan, Lei; Kabagambe, Edmond K.; Song, Yiqing; Tao, Menghua; Zhong, Xiaosong; Hou, Lifang; Shrubsole, Martha J.; Liu, Jie; Dai, Qi; Epidemiology, School of Public Health
    People with fatty liver disease are at high risk of magnesium deficiency. Meanwhile, low magnesium status is linked to both chronic inflammation and insulin resistance. However, no study has investigated the association between intake of magnesium and risk of mortality due to liver diseases. We evaluated the association between total magnesium intake and mortality due to liver diseases in the Third National Health and Nutrition Examination Study (NHANES III) cohort, which included 13,504 participants who completed liver ultrasound examination for hepatic steatosis. Overall magnesium intake was associated with a reduced risk of mortality due to liver disease at borderline significance (P = 0.05). In fully-adjusted analyses, every 100 mg increase in intake of magnesium was associated with a 49% reduction in the risk for mortality due to liver diseases. Although interactions between magnesium intake and alcohol use and hepatic steatosis at baseline were not significant (P > 0.05), inverse associations between magnesium intake and liver disease mortality were stronger among alcohol drinkers and those with hepatic steatosis. Our findings suggest higher intakes of magnesium may be associated with a reduced risk of mortality due to liver disease particularly among alcohol drinkers and those with hepatic steatosis. Further studies are warranted to confirm the findings.